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Abstract
Mucosal antibodies harboring various antiviral activities may best protect mucosal surfaces against early HIV-1 entry at
mucosal sites and they should be ideally induced by prophylactic HIV-1 vaccines for optimal prevention of sexually
transmitted HIV-1. A phase I, double-blind, randomized, placebo-controlled trial was conducted in twenty-four healthy HIV-
uninfected young women. The study objectives were to assess the safety, tolerability and immunogenicity of virosomes
harboring surface HIV-1 gp41-derived P1 lipidated peptides (MYM-V101). Participants received placebo or MYM-V101
vaccine at 10 mg/dose or 50 mg/dose intramuscularly at week 0 and 8, and intranasally at week 16 and 24. MYM-V101 was
safe and well-tolerated at both doses administered by the intramuscular and intranasal routes, with the majority of subjects
remaining free of local and general symptoms. P1-specific serum IgGs and IgAs were induced in all high dose recipients
after the first injection. After the last vaccination, vaginal and rectal P1-specific IgGs could be detected in all high dose
recipients. Approximately 63% and 43% of the low and high dose recipients were respectively tested positive for vaginal P1-
IgAs, while 29% of the subjects from the high dose group tested positive for rectal IgAs. Serum samples had total specific
IgG and IgA antibody concentrations $0.4 mg/mL, while mucosal samples were usually below 0.01 mg/mL. Vaginal
secretions from MYM-V101 vaccinated subjects were inhibiting HIV-1 transcytosis but had no detectable neutralizing
activity. P1-specific Th1 responses could not be detected on PBMC. This study demonstrates the excellent safety and
tolerability of MYM-V101, eliciting systemic and mucosal antibodies in the majority of subjects. Vaccine-induced mucosal
anti-gp41 antibodies toward conserved gp41 motifs were harboring HIV-1 transcytosis inhibition activity and may
contribute to reduce sexually-transmitted HIV-1.Trial Registration: ClinicalTrials.gov NCT01084343 http://www.clinicaltrials.
gov/ct2/show/NCT01084343?term=NCT01084343&rank = 1
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Introduction
The human immunodeficiency virus type 1 (HIV-1) is mainly
transmitted through sexual contact [1]. To infect its host, HIV-1
employs its viral membrane surface trimeric envelope glycopro-
tein, composed of the receptor binding domain gp120 and the
membrane anchored fusion protein subunit gp41 [2,3]. Pathogen
surface proteins are initially detected by the immune system, as
they are easily accessible to the antibodies [4]. This feature
explains why HIV-1 vaccine developers have traditionally
considered the HIV-1 surface gp120/gp41 (gp160) proteins as
good vaccine targets [5].
Since HIV-1 discovery in 1983 [6], more than 150 trials have
tested different HIV-1 vaccine candidates [7,8]. These trials have
almost exclusively focused on systemic responses and were
conducted over 3 chronologically distinct waves of vaccine
research to elicit: 1) Neutralizing antibodies [5,9–13]; 2) T cell-
mediated immune responses [14–20]; 3) Combined neutralizing
antibodies and T cell-mediated immunity [21]. Only the RV144
phase III Thailand trial has provided new hope, providing 31%
efficacy through the induction of non-neutralizing antibodies and
a moderate T cell response [22,23] measured from blood, while
the mucosal immune responses were not investigated during
vaccination. In fact, very few human trials have looked at the
mucosal immune responses following prophylactic HIV-1 vacci-
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nation [24,25] and vaccine-induced mucosal antibodies were
generally not detected. Despite the growing interest for better
comprehension of mucosal immunity in the HIV vaccine field, it
remains challenging and in its infancy.
The focus on the blood immune responses in the past was likely
driven by the following main thoughts: i) The complexity of
studying mucosal immunity due to the difficulty of collecting
mucosal samples that are generally very limited; ii) Mucosal
immunity is too short lived to be monitored; iii) The observed
blood immune responses (humoral and cellular immunity) reflect
what is happening at the mucosal levels. However, for the latter it
was already reported that patterns from paired samples (serum
versus vaginal secretion toward the same antigen) were found to be
different for antibody specificity [26], and antibody function
differences may also exist between blood and mucosa [27,28]. All
these observations are pointing out that both blood and mucosal
compartments should ideally be investigated and compared for
more accuracy.
HIV-1 rapidly crosses the vaginal or anal mucosa within hours
to establish infection. During that period, HIV-1 appears to be
susceptible to immune interference [29] and mucosal immuno-
globulins may represent an efficient front line defense against
sexually transmitted HIV-1 [30-32]. An alternative could be the
development of prophylactic HIV-1 vaccines capable of eliciting
not only circulatory antibodies but also mucosal immune responses
for blocking HIV-1 entry at mucosal sites, before primary infection
takes place locally in the lamina propria. While IgGs may operate in
tissues underlying mucosal epithelium and numerous organs
throughout the body, mucosal IgAs with compartmentalized
distribution and repertoire, combined with their efficient translo-
cation in various mucosal tissues and secretions may best protect
mucosal surfaces [30].
The first protective role of antibodies was demonstrated through
passive transfer in non-human primates (NHP), using neutralizing
IgG antibodies against gp41 and gp120. Early studies have
suggested that high serum neutralizing titers were typically
required for protection against high-dose SHIV mucosal challenge
[5,12,33,34]. More recently, it has been reported that lower serum
neutralizing antibody titers were also protecting against repeated
low-dose mucosal SHIV challenge [11,35].
Human evidence supporting mucosal antibodies as protective
mechanism came from HIV-1 highly exposed persistently
seronegative (HEPS) subjects [36–41]. IgAs purified from HEPS
were able to neutralize infection of peripheral blood mononuclear
cells (PBMC) by HIV-1 isolates [36,38,42,43] and to inhibit HIV-
1 transcytosis across mucosal epithelium in vitro [37,38]. These
inhibitory mucosal antibodies were shown to be specific to gp41
and the QARILAV motif present on the N-helix was one of the
targeted epitopes [44]. A recent study on HEPS women in an
HIV-1 serodiscordant relationship has suggested that exposure to
an HIV-infected partner with low plasma viral load favors the
induction of cervicovaginal IgAs with antiviral activity, which may
contribute to reduce HIV-1 acquisition [45]. The membrane
proximal external region (MPER) of gp41 is also targeted by the
broadly neutralizing IgG monoclonal antibodies 2F5 and 4E10
and more recently by the 10E8 that binds the conserved residues
Trp680 and Lys/Arg683 [46]. Although complete in vivo
protection and sterilizing immunity in NHP were only recently
reported for 2F5 and 4E10 [47], these MPER specific antibodies
were already known for their ability to block HIV transcytosis and
cell infection in vitro [3,48–52], as also observed with mucosal IgAs
from HEPS individuals [53]. All these observations suggest that
gp41 might be an attractive antigen to be included in prophylactic
HIV-1 vaccines.
Gp41 is more conserved than gp120 and mediates the fusion
process with the target cell membrane [54]. It also contains the
conserved mucosal receptor binding motif used by HIV-1 for
binding to the galactosyl-ceramide present on epithelial and
dendritic cells, which corresponds to the P1 peptide originally
defined by the gp41 sequence 650–685 [55]. In a previous study
[27], the P1 and a truncated trimeric recombinant gp41 protein
(rgp41) were modified for allowing lipidation and surface
anchorage on virosome, also called immunopotentiating reconsti-
tuted influenza virosome (IRIV). Virosome has a dual function
[56,57]: i) Lipid carrier for antigen delivery, mimicking the native
viral membrane environment [58], which may be important for
gp41 antigens [59]; and ii) A safe human adjuvant. In contrast to
what was observed with many viral vectors, pre-existing antibodies
against the influenza hemagglutinin (HA) on virosomes may help
to deliver the antigens/virosomes to antigen presenting cells
[60,61] and they are not preventing vaccination with virosomes
[57,62,63].
The HIV-1 candidate vaccine constituted of virosome-P1 and
virosome-rgp41 led to the ‘‘Proof of Concept’’ that vaccine-
induced mucosal antibodies protect NHP against vaginal heterol-
ogous virus challenges [27]. All animals immunized by the
combined intramuscular (priming) and intranasal routes (boost)
were fully protected, as compared to 50% protection for the
animal group that received only intramuscular vaccinations.
Protection was correlated with the presence of gp41-specific
vaginal secretions exhibiting transcytosis inhibition and antibody-
dependent cell-mediated cytotoxicity (ADCC), while serums had
no detectable antiviral activities in vitro. These results have clearly
challenged the paradigm that mucosal protection against sexually
transmitted HIV-1 requires the presence of serum IgGs with virus
neutralizing capacity.
Today, it is broadly accepted that antibodies with various
antiviral functions and from different immune compartments
could play complementary roles for optimal protection [28]. The
next step following encouraging NHP studies was to demonstrate
that similar blood and mucosal antibodies in women could be
induced with the virosome-gp41 approach. It was strategically
decided to focus on the P1 antigen before evaluating in clinic the
combined P1 and rgp41 formulation.
Heterosexual contact is the primary mode of HIV-1 infection
worldwide and it is a rare event [64]. Depending on clinical
studies, HIV transmission probability per unprotected coital act
may range from 1 in 200–2000 for male-to-female transmission, 1
in 200–10,000 for female-to-male transmission and 1 in 10–1600
for male-to-male transmission. About 60% of newly HIV-infected
persons are women and young girls [65], which may also lead to
mother-to-child HIV-1 transmission if not treated. It was decided
to explore first the safety and immunogenicity of the vaccine in the
dominant target population, while testing in men is planned for
subsequent trials.
Here we present an exploratory Phase I ‘‘Proof of Principle’’
conducted in healthy young women with the primary objective to
determine the safety and tolerability of virosome-P1 (MYM-V101).
The second objective was to evaluate its immunogenicity in the
serum, while monitoring specific antibodies at the vaginal and
rectal levels and conducting limited functional assays were part of
the ancillary objectives.
Methods
Study design and ethics
This monocenter double-blind, randomized, placebo-controlled
Phase I study was registered at www.clinicaltrials.gov (registration
Virosome-P1 Phase I Safety and Immunogenicity
PLOS ONE | www.plosone.org 2 February 2013 | Volume 8 | Issue 2 | e55438
NCT01084343) and conducted at the Center for Vaccinology
(CEVAC), Ghent University Hospital (Belgium). The protocol for
this trial and supporting CONSORT checklist are available as
supporting information; see Protocol S1 and Checklist S1 and.
Trial protocol, substantial amendments, signed written subject
information/Informed Consent Forms (ICFs) and subject diaries
were reviewed by the Independent Ethics Committee (IEC) that
gave on October 8th 2009 the written approval for this study
conducted in accordance with the Declaration of Helsinki and
Good Clinical Practice. The approbation and authorization to
conduct the clinical trial was also received from the Federal
Agency for Medicines and Health Products (FAGG) in Belgium.
Due to the exploratory character of the study, no formal power
calculation was performed.
The primary objective of the trial was to evaluate the safety and
tolerability of two doses of a candidate prophylactic HIV-1 vaccine
administered by the intramuscular and intranasal routes. The
secondary objective of this Phase I was to verify the immunoge-
nicity of the vaccine candidate by the quantification of P1-specific
IgGs and IgAs in the serum. Ancillary studies were also conducted
with vaginal and rectal secretions to assess the presence of mucosal
P1-specific IgGs and IgAs and their capacity to block in vitro HIV-1
infection and transcytosis. PBMC were also isolated to measure
the cellular immune responses.
Double-blinding of volunteers’ randomization, data manage-
ment, and descriptive statistics for the analysis of safety, tolerability
and immunogenicity data were conducted by Kinesis Pharma
B.V. (Netherlands) and M.A.R.C.O. GmbH & Co (Germany).
Type of randomisation was 2 strata of 12 subjects each. In each
stratum a weight of 2:1 (active treatment:placebo) was used, no
blocks were used within a stratum.
Twenty four (24) Caucasian women were included and
randomized in 2 groups (Figure 1 showing the Flow Chart) and
enrolled by CEVAC, who has been responsible for the sample
work up of the collected materials: A low dose (LD) group (10 mg/
dose) and a high dose (HD) group (50 mg/dose). In each group, 8
subjects received the active treatment with MYM-V101 and 4
subjects received the placebo (MYM-IRIV). Four vaccine doses
were administered; two intramuscular injections at week 0 and 8,
and two intranasal administrations at week 16 and 24. Day of
vaccination was to match the woman’s cycle (see figure addendum
S2 in Protocol S1), with vaccine administration between Days 1 to
5 after ovulation, allowing medical visits to take place 6 to 8 days
later to monitor antibody levels. This time frame corresponds to a
period of the menstrual cycle with lower risk of antibody
contamination originating from menstrual bleeding and lower
mucus antibody trapping that could reduce the recovery yield of
antibodies. There were no deviations for the intramuscular
injections, all were administered according to the protocol, while
a single minor deviation for one subject during the 4th
administration (second intranasal administration) was reported
and it had no impact on the data. The study encompassed 12
medical visits: Screening/week 25, Baseline/week 23, Visit 1/
week 0, Visit 2/week 1, Visit 3/week 4, Visit 4/week 8, Visit 5/
week 9, Visit 6/week 16, Visit 7/week 17, Visit 8/week 24, Visit
9/week 25 and Visit 10/week 29. Data of subjects receiving
Figure 1. Study flow chart. All subjects screened, enrolled and randomized are indicated in the chart. A total of 24 subjects divided over 2 panels
of 12 subjects, which was deemed sufficient to meet the objectives of this trial. The study encompassed 12 medical visits, supplemented by physical
examination, recording of vital signs and body temperature, as well as collection of blood samples for safety evaluation. Interim safety reviews have
been done prior to the second vaccine administration for each route and prior to start of the HD regimen. Serum (week23, 0, 1, 4, 8, 9, 16, 17, 24, 25
and 29), vaginal (week 23, 17, 25 and 29) and rectal samples (week 23 and 25) were taken for secondary endpoint and ancillary studies. To evaluate
the cellular immune response, PBMC were isolated on weeks 23, 1, 9, 17 and 25. One subject from HD withdrew consent after Visit 5/week 9, which
includes the first two intramuscular injections and performed the early withdrawal visit at the time point of week 16. Consequently, safety and
immunogenicity analyses were done only from visit 1 to 5. Rectal samples of 2 LD subjects at Baseline were discarded by mistake during sample
work-up. Without baseline data, induction of rectal specific antibodies above baseline could not be estimated. LD: Low dose; HD: High dose.
Allocation to a panel was done in consecutive order; Panel 1 (LD: number 101 to 112) was filled first followed by Panel 2 (HD: number 201 to 212). In
each panel, 8 subjects received active treatment with MYM-V101 and 4 subjects received placebo MYM-IRIVm or MYM-IRIVn in a double-blind way.
doi:10.1371/journal.pone.0055438.g001
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placebo were pooled for comparison with the low and high dose
groups.
Study population
Participants were negative for serological markers of HIV-1,
HIV-2, HAV, HBV and HCV infections, aged between 18 and
45 years with a body mass index (BMI) between 18.0–30.0 kg/m2
(Table 1) and were not suffering or had not suffered from recurrent
vaginal infections or sexually transmitted diseases within one year
prior to vaccination. Women had regular menstrual cycles (24 to
30 days) and were healthy, based on a medical evaluation
revealing no clinically relevant abnormality after physical and
gynecological examinations, medical history, electrocardiogram,
vital signs, blood biochemistry and hematology tests, urinalysis.
Subjects with childbearing potential agreed to use adequate oral
contraception or physical barrier contraceptives. Descriptive
statistics (n, arithmetic mean, standard deviation, median,
minimum, and maximum) were generated at all visits by treatment
group.
Study vaccines
The original published P1 peptide sequence [55] was modified
(SQTQQEKNEQELLELDKWASLWNWFDITNWL-
WYIKLSC) for allowing lipidation of the peptide for anchorage
into the virosome membrane and to accommodate industrial up-
scaling. GMP manufacturing was according to ICH Q7 (Bachem
AG, Switzerland). Vaccine formulations were manufactured by
Pevion Biotech AG, as previously described [27,66]. Vaccine
MYM-V101 m for intramuscular injections (0.5 mL, 23G x 1
inch needles) were at 20 mg/mL (LD) or 100 mg/mL (HD) of
specific P1 content, while MYM-V101n for intranasal adminis-
tration by BD AccusprayTM (0.1 mL/nostril) were at 50 mg/mL
(LD) or 250 mg/mL (HD), all containing about 10 mg of influenza
hemagglutinin per dose unit. Placebo consisted of influenza-
virosome without P1: MYM-IRIVm or MYM-IRIVn. The
vaccines were packaged and labeled in double-blinded manner.
A minimal shelf-life of nine months was demonstrated. Modifica-
tion of P1 by oxidation and de-amidation over time was observed
by LC-MS. For safety concerns, dose adjustments consisting in a
reduction of 40–50% of lipidated P1 for the last 3 injections were
made in the HD group.
Safety and reactogenicity evaluation
The primary endpoints within one week after each vaccination
were: 1) Solicited local symptoms (redness, swelling, pain in case of
intramuscular vaccination and nasal congestion, runny nose,
impaired smelling and headache in case of intranasal vaccination);
2) Solicited general symptoms (body temperature, tiredness,
gastro-intestinal complaints, malaise, muscle pain). Serum C-
reactive protein (CRP) values were used as secondary endpoint for
the safety analysis. Descriptive statistics (n, arithmetic mean,
standard deviation, median, minimum, and maximum) were
computed for each symptom and each time point (days 0 to 6 after
vaccinations) by treatment group. Spontaneous adverse events
(AEs) that might have occurred from Weeks 2–8 after each
vaccination were also recorded. The study encompasses a
Baseline/week 23 visit and 10 medical visits for monitoring
occurrence of hematological and biochemical abnormalities from
blood. Safety data of subjects receiving placebo were pooled for
comparison with the low and high dose groups.
Collecting serum and mucosal samples
Blood samples were drawn by venipuncture, using vacuum
collection tubes. Vaginal samples at Baseline were obtained by
four sequential vaginal harvestings in different segments at 1
minute interval, using pre-wetted Weck-CelH sponges (Eyetec
Ophthalmic product, Altomed Ltd., UK) with 50 mL of sterile PBS
that were placed gently in the vagina and allowed to passively
adsorb secretions for approximately 30 seconds, as previously
described [67,68]. For post-vaccination visits at week 17, 25 and
Table 1. Characteristics of the study population.
Placebo n = 8 MYM-V101 (Low Dose) n = 8 MYM-V101 (High Dose) n = 8
Age (year)
Mean (SD) 23.3 (3.0) 24.1 (3.5) 23.6 (3.2)
Median 22.0 23.0 23.0
Range 20–28 19-29 19–29
Weight (kg)
Mean (SD) 66.5 (7.4) 66.4 (12.7) 58.7 (7.6)
Median 66.2 66.6 61.0
Range 57–79 51–82 47–69
Height (cm)
Mean (SD) 169.9 (4.6) 169.0 (7.9) 166.8 (6.3)
Median 171.0 166.0 167.0
Range 162–176 159-182 158–176
BMI (kg/m2)
Mean (SD) 23.1 (3.3) 23.1 (3.6) 21.1 (2.1)
Median 22.4 22.3 20.8
Range 19–30 19–30 18–24
Ethnicity (n)
Caucasian 8 8 8
doi:10.1371/journal.pone.0055438.t001
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29, only two sequential harvestings were performed. Rectal
samples were obtained at Baseline and week 25, following two
sequential harvestings at 5 minutes interval with Weck-CelH. Each
sponge was macroscopically checked for blood traces and weighed
prior being placed in the upper part of a sterile Spin-X centrifuge
tube filter. Vaginal extraction from the sponge was performed as
follow: Each sponge was equilibrated with 300 mL of extraction
buffer for 30 minutes at 4uC, as previously described: PBS, 0,25 M
NaCl, supplemented with protease inhibitor cocktail diluted 1/100
from the freshly made master mix, 100 IU/mL penicillin, 100 mg/
mL streptomycin. Protease inhibitor cocktail (master mix 100x)
was containing 100 mg/mL aprotinine, 500 mg/mL leupeptine,
hemisulfate salt, 100 mg/mL bestatine hydrochloride, 50 mg/mL
AEBSF (all from Sigma). Following centrifugation at 12,000 g for
20 minutes at 4uC, a second extraction was performed with the
same volume and the extracted vaginal secretions of the same
subject were pooled, distributed in aliquots and stored at 280uC.
All pre-specified laboratory assessments were conducted in a
blinded manner.
Immunogenicity and statistical evaluation
Pre-immune and immune samples were analyzed for total and
specific antibody-response on the Immuno-PCR ImperacerH
platform [69-72], which combines ELISA and PCR technologies,
using detecting antibodies conjugated to DNA sequences for
improved sensitivity. For analysis of total antibody-response, anti-
human IgG or IgA antibodies were used as surface immobilized
capture-reagent. For detecting vaccine-induced P1 specific anti-
bodies, surface immobilized P1 peptide was used to which serum
or mucosal samples were added, followed by anti-human IgG or
IgA antibodies.
The ImperacerH-reader provides Ct value (raw data), the
calculated cycle time: Ct = the number of PCR cycles needed to
reach a uniform threshold of antibody-DNA conjugates (dRn
signal), which is the measured fluorescence increase. Ct value is
allowing quantitative analysis of analyte against a calibration-
curve. As Ct is inversely proportional to the antigen concentration,
it was converted to delta Ct (DCT) value, which is directly
proportional to initial antigen concentration: DCt = Ctmax – Ct
value, Ctmax corresponding to the maximum number of cycles by
PCR.
The precision of the methods was determined in 6 replicates
(n = 6) during validation. A cut-off DDCT value was used to define
a sample positive for P1-specific antibodies. The DDCT value was
calculated as follow: i) The highest standard deviation (SD) value
of the assay (0.917) was used as SD cut-off value, which was
calculated from the intermediate precision expressed as standard
deviation (n = 6) of the assay derived from a negative control
sample (mean DCT =15); ii) This standard deviation was
multiplied by the factor 2.177 proposed when n=6 to calculate
the cut-off for 95% confidence level [73] (SD cut-off value = 0.917
[SD; n= 6; mean DCT =15]62.177 [95% CL; n= 6] = 1.996);
iii) The mean DCT value from baseline (pre-immune) was
subtracted from the mean DCT value from immune sample,
leading to DDCT value. Any sample with a DDCT value .1.996
was considered as positive for the presence of P1 specific
antibodies. Based on assumptions and internal standard curves,
DCT values from ImperacerH were converted to approximate
antibody concentrations (ng/mL) by analysis against a reference
curve. Converting data from arbitrary unit to antibody concen-
tration is an approximate approach and dependent on the
technique used. Therefore, the estimated antibody concentrations
should be considered only as indicative values.
In this study, immunological parameters were expected to show
skewed non-normal distributions. In that case, log transformation
of the skewed data was considered. In case of normally distributed
log transformed data, these were used in a paired t-test analysis.
When the log transformed data were not normally distributed, the
Wilcoxon signed rank-sum test was used to compare pre- and post-
vaccination results. Because of the explorative nature of this study,
there were no adjustment of statistical p values for multiple time
point assessments for immunological analysis of both serum and
mucosal samples. Significance of statistical results was interpreted
only for the time points of primary interest. Statistical testings for
other time points were only interpreted as a descriptive tool to help
quantify the differences from baseline over time.
Th1 responses
Cellular Th1 immune responses were measured, as previously
described [74]. Briefly, PBMC with viability .95% were cultured
in vitro in the presence of co-stimulatory anti-CD28 and anti-
CD49d monoclonal antibodies (1 mg/mL each; BDIS) with/
without P1 peptides (1.25 and 5 mg/mL). Staphylococcal entero-
toxin B (SEB; 1 mg/mL; Sigma-Aldrich) was used as a positive
control for cell activation. Intracellular cytokine staining was
performed to detect IFNc, TNFa and IL-2 in CD3+/CD4+,
CD3+/CD8+, CD3+/CD56+ and CD32/CD56+ cells.
Table 2. Volunteers experiencing solicited local and general symptoms after intramuscular vaccination.
Group n No. of Symptoms Redness Grade Swelling Grade Pain Grade
Body Temp. (oC)
min-max
0 1 2 3 0 1 2 3 0 1 2 3
Placebo
Injection #1 8 2 8 0 0 0 8 0 0 0 6 2 0 0 35.1–37.5
Injection #2 8 2 8 0 0 0 8 0 0 0 6 2 0 0 35.2–37.3
Low Dose
Injection #1 8 2 8 0 0 0 8 0 0 0 6 2 0 0 35.6–37.3
Injection #2 8 2 8 0 0 0 8 0 0 0 6 2 0 0 35.3–37.3
High Dose
Injection #1 8 4 8 0 0 0 8 0 0 0 4 4 0 0 35.3–37.4
Injection #2 8 2 7 1 0 0 8 0 0 0 7 1 0 0 35.9–37.8
doi:10.1371/journal.pone.0055438.t002
Virosome-P1 Phase I Safety and Immunogenicity
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e55438
Functional in vitro assays
Immunoglobulins from some samples were concentrated by
ammonium sulfate precipitation [75,76] for reaching a higher
antibody concentration before being tested in neutralization
assays. Enriched mucosal antibodies were tested in two neutral-
ization assays (U87.CD4.CCR5 and TZM/bl), using three
different HIV-1 strains (JRFL-140WT, QH0692.42 and SF162).
2F5 IgG (5 mg/mL for IC50 and 50 mg/mL for IC90) was used as
positive control. Samples with low antibody concentration were
pooled and those with acceptable antibody concentration were
tested individually. Neutralization assays were performed as
described previously [77,78]. For inhibition of HIV-1 transcytosis
assays [79–81], clade B (JR-CSF) HIV-1 infected CCR5-CEM
cells were used to inoculate HEC-1 endometrial cell lines cultured
in a polarized manner in a two-chamber system. 2F5 IgG was used
as positive control (10 mg/mL .90% HIV-1 transcytosis inhibi-
tion, data not shown). Percentage of transcytosis inhibition was
determined in three independent experiments. Samples were
defined as positive when the transcytosis inhibitions were above
50% and reproduced in at least 2 experiments. The 2F5 IgG
monoclonal antibody was used as positive control: Transcytosis
blockade efficiency = 100 – Transcytosis efficiency (Transcytosis
in presence of vaginal samples from week 25 or week 29/
Transcytosis in presence of pre-immune sample) 6100. A
qualitative approach (presence of absence of antiviral activity)
was used for monitoring the presence of transcytosis inhibition
activity. Due to the limited number of samples and assay
variability, statistical analyses according to clinical standards were
not conducted.
Results
Study population
Thirty eight women were screened for eligibility and twenty
four were enrolled in the study (Figure 1). The trial was conducted
according to the planned protocol: Screening for Low dose and
High dose was from November 4th 2009 to January 12th 2010, the
treatment/vaccination period was from December 8th 2009 to
August 2nd 2010 and the follow up period (post vaccination) was
from June 2nd 2010 to September 28th 2010, the latter one
corresponding to trial completion after the final medical visit of the
last vaccinated subject. Prior to vaccination, medical examinations
had shown that all subjects were in good health. The mean age of
the Caucasian female subjects of this study was 23.7 years, ranging
from 19 to 29 years (Table 1).
Safety analyses
The majority of subjects remained free of local and general
symptoms after vaccination (Table 2 and Table 3). Grade 1 pain at
the injection site was reported after the first and second
intramuscular dose by two subjects from both LD and placebo
groups. In the HD group, Grade 1 pain was reported by four and
one persons after the first and second injection, respectively
(Table 2). Grade 1 redness was reported only once by a HD
recipient after the second injection. No swelling was reported.
After the first intranasal administration, one LD and two HD and
placebo recipients reported nasal congestion. After the second
intranasal dose, two HD and two placebo recipients complained of
nasal congestion. Runny nose (Grade 1) or headache (Grade 1 to
3) were reported by only few subjects and smelling impairment by
none. CRP values (data not shown) and the incidences of local and
general symptoms (including body temperature) appeared to be
similar between the different groups, and most of these resolved
within 48 h.
Two subjects in LD and one subject in HD reported
spontaneous vaccine-related AEs. In LD, one subject had an
ecchymosis at the injection site on the day of the first
intramuscular vaccination, and she also reported dizziness after
the first intramuscular vaccination that resolved on the same day.
The other LD subject had an ecchymosis at the injection site
following the second intramuscular vaccination. The HD subject
reported tickling in the right nostril one minute after the first
intranasal vaccination, which resolved on the same day and did
not occur after the second intranasal vaccination. All four vaccine-
related AEs were of mild intensity and resolved spontaneously.
None of the subjects in the placebo group reported a vaccine-
related AE. Incidences of non-related AEs did not differ between
groups. No AE led to trial discontinuation and no serious AEs
Table 3. Volunteers experiencing solicited local and general symptoms after intranasal vaccination.
Group n No. of Symptoms
Nasal Congestion
Grade Runny Nose Grade
Impaired
Smelling Grade Headache Grade
Body Temp.
(oC) min-max
0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3
Placebo
Injection #3 8 5 6 2 0 0 8 0 0 0 8 0 0 0 5 1/2 0 0 35.3–37.2
Injection #4 8 7 6 1/1 0 0 4 2/2 0 0 8 0 0 0 7 0 1 0 35.4–37.2
Low Dose
Injection #3 8 2 7 1 0 0 8 0 0 0 8 0 0 0 7 0 1 0 35.3–37.2
Injection #4 8 2 8 0 0 0 8 0 0 0 8 0 0 0 6 2 0 0 35.9–37.3
High Dose
Injection #3 7 7 4 2 1 0 5 2 0 0 7 0 0 0 5 1 1 0 35.4–37.3
Injection #4 7 4 5 2 0 0 6 1 0 0 7 0 0 0 6 0 0 1 35.7–37.2
Table 2 is showing AEs following intramuscular vaccinations and Table 3 for intranasal administrations. Local and general symptoms were assessed from Day 0 to Day
6 after each vaccination and spontaneous AEs that might have occurred after each vaccination were also recorded. The study encompasses a Baseline/week 23 visit
and 10 medical visits to monitor occurrence of hematological and biochemical abnormalities in blood. Each symptom was graded for severity and assigned causality
relative to the study vaccine. Severity was graded as either absent/none (Grade 0), mild (Grade 1, easily tolerated), moderate (Grade 2, interfere with activity of daily
living), or severe (Grade 3, prevented activities of daily living). Redness and swelling at the injection site were graded as follow: 0 =,5 mm, 1 = 5–20 mm, 2 = 20–50 mm,
3 =.50 mm. Numbers in bold are vaccine-related symptoms.
doi:10.1371/journal.pone.0055438.t003
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were reported. All other safety parameters assessed did not reveal
any clinically significant findings.
Immunogenicity analyses
Based on ImperacerH DCT values shown in Figure 2, a clear
increase of P1-specific IgGs and IgAs in serum was observed
within one month (week 4) after the first vaccination (week 0) in
both LD and HD vaccinated recipients, respective to pre-immune
baseline (week 23). This increase was further boosted by the
second intramuscular vaccination, as shown at week 9. In LD
recipients, the third injection given intranasally at week 16 had no
significant boosting effect on the serum P1-specific IgGs and IgAs.
In HD vaccinees, the third injection had a clear boosting effect
only on the serum P1-specific IgGs (p= 0.004). The fourth and last
vaccination at week 24 had no significant impact on serum P1-
specific IgG and IgA increase for both groups.
The mucosal responses in both LD (Figure 2H, p= 0.001) and
HD (Figure 2I, p,0.001) vaccinated subjects showed a clear
increase of P1-specific IgGs in vaginal samples at week 17, as
compared to pre-immune vaginal samples (Baseline/week –3),
Figure 2. Serum and mucosal anti-P1 specific antibody responses. The presence of P1-specific IgGs and IgAs was measured by ImperacerH
and data are presented as the mean DCT value from pre-immune (Baseline/week 23) and immune samples (week 0 to week 29). Panels A, D, G and J
are for the placebo, Panels B, E, H and K are for the LD, Panels C, F, I and L are for the HD. To determine if DCT values of immune samples were
significantly increased, respective to pre-immune samples (week 23), p values for serum samples were calculated for weeks 8, 9, 16, 17, 24, 25, and
for vaginal samples weeks 17, 25 and 29. For determining if the injected vaccine had a boost effect, respective to the previous vaccination, p values
were also estimated between weeks 9–17 (2nd versus 3rd injection) or 17–25 (3rd versus 4th injection): *0.01,p,0.05, **0.001,p,0.01, ***p,0.001.
NS (not significant), t (trend), LD (low dose), HD (high dose). Whisker 10–90% percentile with minimum, maximum and median. Normally distributed
immunological data were tested by paired t-test whereas for non-normal distributed data, the Wilcoxon signed rank-sum test was used to compare
pre- and post-vaccination results.
doi:10.1371/journal.pone.0055438.g002
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while the fourth injection did not elicit a significant increase of the
antibody levels. Except for week 29 in the LD group, vaginal P1-
specific IgAs for both groups did not reach statistical significance.
Rectal P1-specific IgGs were also detected in both LD (Figure 2K,
p= 0.003) and HD (Figure 2L, p,0.001) vaccine recipients at
week 25, while P1-specific IgAs could be measured only in HD
vaccinees (Figure 2L, p = 0.034).
To avoid missing important mucosal observations either due to
group analyses, high background values from pre-immune samples
and/or IgA level fluctuations within the same person, responders
were evaluated individually, using the 1.996 cut-off DDCT value
for weeks 17, 25 and 29, respective to baseline (Table 4 and
Table 5). Regarding vaginal P1-specific IgGs in LD and HD
groups, all subjects were positive 1 week after the fourth injection.
In the placebo group, 1 out of 8 subjects tested positive at week 17
and another 1 out of 8 subjects at week 25. As opposed to constant
detections of IgGs, detections of vaginal P1-specific IgAs were
varying within subjects of the LD and HD, depending on the time
points.
The change from baseline was also calculated per visit (Table 5).
Among the 15 subjects of the LD and HD, only two subjects (one
per group) had vaginal samples positive for P1-specific IgAs in 3
out of 3 visits (week 17, 24 and 29), while the other subjects had 1
or 2 positive samples out of 3 visits. In LD, 5 out 8 subjects (62.5%)
had at least one vaginal sample containing P1-specific IgAs at
either week 17, 25 or 29. In HD, 3 out 7 subjects (42.9%) had at
least one positive vaginal sample.
In rectal samples specific-IgGs were present in 83% and 100%
of LD and HD subjects, respectively (Table 4). Rectal specific-IgAs
were detected in 29% of HD subjects. The mean serum (Table 6)
and mucosal (Table 7) P1-specific IgG and IgA concentrations are
shown as indicative values. For serum, the mean P1-specific
antibody concentrations are ranging from 380 to 605 ng/mL for
IgGs and 30 to 53 ng/mL for IgAs, respective to high and low
dose. Mucosal P1-specific IgG antibody concentrations at the end
of the trial (Visit 10/week 29) are ranging from 1.73 to 5.96 ng/
mL, while for IgA values are 0.07 to 0.22 ng/mL.
Cellular immune responses
Although the MYM-V101 vaccine formulation was primarily
designed to trigger antibodies, it was estimated that it could
potentially elicit also a Th1 response. Therefore PBMC were
stimulated with P1 peptides and intracellular cytokine induction
(IFNc, TNFa?IL-2) was analyzed by FACS. No P1-specific
induction of cellular immune response in CD4+ or CD8+ T cells
and NK cells could be revealed (data not shown).
Evaluation of anti-viral activities
Due to limited mucosal material, not all subjects could be tested.
Based on the presence of P1-specific IgG and/or IgA antibodies
and the available specimen volume, selected samples were tested
for in vitro antiviral activities. The genetically engineered TZM-bl
cell line was tested with the clade B laboratory strain SF162 and
the primary strain QHO692.42, while the U87.CD4.CCR5 cell
line was tested with the JFRL-140WT. No neutralization of HIV-1
was found for all samples tested (data not shown).
Analyses on vaginal samples from the same subset of subjects
were tested for their capacity to block HIV-1 transcytosis in vitro
(Figure 3), with the mean percentage inhibition provided only as
indicative value for a qualitative assessment. Vaginal samples of
two out of two subjects of LD displayed 79–90% transcytosis
inhibition at weeks 25 and 29. For HD at week 25, four out of five
subjects were found positive (75–96%), while at week 29, four out
of six subjects were positive (59–84%). Vaginal samples from the
placebo group had no significant transcytosis inhibition. Some
samples had no significant levels of IgA antibodies (DDCT ,1.996
cut-off), despite high transcytosis inhibition. However, if both P1-
specific vaginal IgGs and IgAs are considered, the antiviral activity
is consistently observed in 12 out of 15 samples (LD and HD).
Discussion
Neutralizing antibodies and cytotoxic T cells play certainly an
important role in eradicating or containing viral infection but they
represent the ‘‘tip of the iceberg’’ of the arsenal potential of the
immune system. Because HIV-1 is mainly acquired at mucosal
sites, mucosal immune responses that interfere with HIV-1
attachment and migration across the mucosa, and promote viral
clearance may contribute also to prevent sexual HIV-1 transmis-
sion. Protective mucosal antibodies could be elicited in the female
genital tract by vaginal vaccination but this administration route
poses several challenges and may require a mucosal adjuvant in
order to induce an optimal immune response [82–85].
We have designed a prophylactic HIV-1 vaccine candidate that
is potentially capable of protecting the initial sites of viral entry,
especially the female genitals and the rectum, by inducing a
mucosal humoral immune response without the need of local
vaccination. The proposed MYM-V101 candidate HIV-1 vaccine
was tested in a Phase I ‘‘Proof of Principle’’ to evaluate its safety
and tolerability, when administered via intramuscular and
intranasal routes in healthy young women.
The rationale for this immunization regimen was based on the
postulate that intranasal priming may not be very efficient unless a
potent mucosal adjuvant is added to the formulation. However,
vaccination by intranasal route without adjuvant could work more
efficiently if applied as a boost, following adequate priming via the
intramuscular route. Although such immunization regimen may
be less practical for medical care providers, it may minimize safety
and regulatory concerns if mucosal adjuvant is absent from the
vaccine. MYM-V101 can be considered as a safe vaccine that is
Table 4. Percentage of subjects with measured mucosal anti-P1 specific antibodies at each visit.
Vaginal Antibodies Rectal Antibodies
Week 17 (Visit 7) Week 25 (Visit 9) Week 29 (Visit 10) Week 25 (Visit 9)
IgG IgA IgG IgA IgG IgA IgG IgA
Placebo 12.5% (1/8) 0% (0/8) 12.5% (1/8) 0% (0/8) 0% (0/8) 12.5% (1/8) 12.5% (1/8) 12.5% (1/8)
Low Dose 87.5% (7/8) 50% (4/8) 100% (8/8) 12.5% (1/8) 100% (8/8) 37.5% (3/8) 83.3% (5/6) 16.7% (1/6)
High Dose 100% (7/7) 28.6% (2/7) 100% (7/7) 42.9% (3/7) 100% (7/7) 14.3% (1/7) 100% (7/7) 28.6% (2/7)
doi:10.1371/journal.pone.0055438.t004
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well tolerated, when administered by the intramuscular (Table 2)
and intranasal (Table 3) routes at the tested concentrations. No
significant difference could be observed between the safety results
of vaccinated groups and placebo recipients.
Very few HIV trials have tried without success to monitor
mucosal antibodies during prophylactic vaccination [24,25]. We
may postulate that the detection assays employed at that time were
not sensitive and robust enough for quantifying very low levels of
specific mucosal antibodies. For our trial, we have developed the
ImperacerH, a fast, robust and ultrasensitive detection assay [69-
72] already used by pharmaceutical industries for other applica-
tions, which is suitable for detecting specific low mucosal antibody
concentrations in the range of pg to ng/mL. The assay is
fundamentally based on ELISA but the antibody-enzyme conju-
gates are replaced by antibody-DNA conjugates, which can be
amplified by PCR [69,70]. This technique was validated during
clinical development and it allows reliable detection of antibodies
in serum and mucosal samples, offering also the main advantage of
consuming few mL.
The vaccine MYM-V101 has induced P1-specific IgG and IgA
responses in serum already within 4 weeks after the first
vaccination (Figure 2). There is a clear benefit of the first two
intramuscular injections for triggering the systemic humoral
response. The third vaccine dose given intranasally elicited only
a significant antibody boost of serum IgGs in the HD group. No
clear effect of the third dose was seen on serum IgA levels and no
booster effect of the fourth dose could be demonstrated. Currently,
it cannot be excluded that the third and fourth vaccine doses may
have a beneficial effect by improving the affinity and/or the
antiviral capacity of the elicited antibodies, as well as improving
the memory response. However, this needs to be investigated
further.
One month after the last vaccination, vaginal and rectal P1-
specific IgGs were detected in almost all vaccinees. The P1-specific
IgGs found in mucosal samples may be strictly derived from local
production but can also partially have a circulatory origin. Due to
unexpected high pre-immune vaginal reactivity toward the P1
antigen (high pre-immune DCT value) observed in some subjects,
the analysis per group did not reveal a significant increase in
mucosal P1-specific IgAs in immune samples. Unspecific binding is
always possible but the observed reactivity could also be due to
specific binding detected by the ultrasensitive ImperacerH tech-
nique. We may postulate that pre-immune sample reactivity could
be related to: i) The presence of auto-antibodies against self
proteins that cross-react with HIV-1 gp41 motifs, since HIV-1 is
known to share several human protein homologies [86–88]; or ii)
Subjects were exposed to HIV-infected individuals prior to this
study and have developed specific mucosal anti-gp41 antibodies,
while remaining seronegative, as reported in HIV exposed-
seronegative (HESN) individuals [45]. The latter hypothesis is
very unlikely, considering the ‘‘profile’’ of our volunteers but we
cannot exclude this possibility. More investigations would be
needed to further explore these possibilities but it was not the
objective of this exploratory study conducted on limited number of
subjects.
When DCT values of immune samples were individually
considered and compared to their corresponding pre-immune
DCT values, many subjects taken separately had a DDCT value
(DCT immune – DCT pre-immune) above the 1.966 cut-off,
suggesting a net increase of mucosal P1-specific IgAs after
vaccination with MYM-V101 (see Tables 5). P1-specific IgAs
were detected in vaginal samples of 63% (LD) and 43% (HD) of
the subjects with at least one positive mucosal sample out of three.
We have noticed that detection of vaginal P1-specific IgAs seems
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to pose a big challenge due to the variation that occurs over time
within a single individual. This may be explained in part by the
hormonal and menstrual cycle fluctuations already reported
[83,84], which could influence the amount of IgAs already low
in the women vagina, while IgAs in the endocervix are more
abundant and easier to detect. The low level of IgAs, respective to
IgGs was expected in the vaginal secretion but the low frequency
of positive samples may also point towards a technical problem, as
IgA is the dominant antibody isotype in the lower intestinal tract.
The current antibody detection methodology and rectal harvesting
technique will require further optimization for optimal IgA
detection.
To alleviate the study burden for the participants, the collection
of mucosal samples on week 9 (one week after the second
intramuscular injection) was abandoned. Therefore, the benefit of
the third injection (first intranasal administration) on mucosal
antibodies is difficult to appreciate at this stage. Meanwhile, it is
known that intranasal vaccination may solicit distant mucosal and
systemic immune responses [82,89], depending on the induction of
specific sets of homing receptors during the interaction on T and B
cells with mucosal dendritic cells [90,91]. However, activation of
the mucosal responses at the vaginal and intestinal levels by the
intramuscular route, using non-replicative vectors like virosomes
might be more an exception than the rule. In an upcoming clinical
trial, additional mucosal samples will be collected to clarify the
respective contribution of the intramuscular and intranasal route
for the induction of mucosal immunity. The available data allows
us to conclude that MYM-V101 has successfully induced specific
mucosal antibodies.
At the end of the study (week 29, Tables 6 and 7), the mean total
P1-specific antibody concentration in vaginal samples (LD:
6.18 ng/mL and HD: 1.6 ng/mL) is at least 100-fold lower than
serum samples (LD: 658 ng/mL and HD: 410 ng/mL). These low
mucosal antibody concentrations preclude their successful testing
in current in vitro neutralization assays, which were initially
developed for serum samples and generally require at least
200 ng/well of neutralizing specific antibodies [78]. Currently, we
cannot exclude the presence of low levels of neutralizing antibodies
in vaginal or rectal fluids and antibody purification might be
necessary for detecting them. Meanwhile, adding purification steps
for specific IgGs and IgAs could introduce risks of losing or
affecting the quality of samples and this approach might not be
easily applicable to clinical trials evaluating thousands of samples.
It might be more realistic to improve the in vitro neutralization
assay sensitivity by at least 100-fold, ideally requiring less than 1
ng/well of specific antibodies for reliable testing of low amount of
unpurified mucosal samples.
Although few ng/mL of specific mucosal antibodies might be
perceived as a very low antibody concentration in the vaccine
field, respective to serums that generally contain mg/mL of specific
antibodies, it still represents billions of antibodies per mL of
vaginal secretion. Furthermore, it is likely an underestimation,
considering the contribution of the mucosal antibodies also
trapped in the mucus or located in the lamina propria underneath
the mucosal tissue that could not be estimated from the collected
secretion samples of this study.
Transcytosis inhibition was investigated only for vaginal
samples, as our previous studies had shown that circulatory
antibodies could not inhibit HIV-1 transcytosis [27] and rectal
samples were too limited. Although the transcytosis assay has been
standardized to some extent in various laboratories, variations are
inherent to in vitro cell-based assays and very often, experiments are
conducted at least twice for confirming the in vitro observations.
Transcytosis assay was developed to obtain robust data (qualitative
observation) but was not formally qualified, as it is done for bio-
analysis of the active pharmaceutical ingredient. Acting as a
candidate biomarker for induction of functional mucosal immu-
nity, transcytosis assay may provide reliable data for detecting
antiviral activities, such as antibodies interfering with HIV-1
passage across in vitro cell monolayer, mimicking the mucosal
epithelium found in the endocervix or intestinal tract. Eighty
percent of the vaginal samples were inhibiting HIV-1 transcytosis
(Figure 3), as opposed to placebo samples that had no activity. For
some mucosal samples, discrepancies were found between the
Table 7. Approximate vaginal and rectal P1-specific antibody concentrations.
Vaginal Antibodies (ng/mL) Rectal Antibodies (ng/mL)
P1-specific IgGs P1-specific IgAs P1-specific IgGs P1-specific IgAs
Baseline
V7
(w17)
V9
(w25)
V10
(w29) Baseline
V7
(w17)
V9
(w25)
V10
(w29) Baseline
V9
(w25) Baseline
V9
(w25)
Placebo (n) 8 8 8 8 8 8 8 8 8 8 8 8
Mean 0.03 0.06 0.04 0.03 0.12 0.03 0.12 0.65 0.02 0.01 0.26 0.15
SD 0.02 0.08 0.03 0.03 0.17 0.06 0.24 1.67 0.02 0.01 0.22 0.09
Median 0.03 0.04 0.04 0.03 0.05 0 0.03 0.04 0.01 0 0.2 0.13
Low Dose
(n)
8 8 8 8 8 8 8 8 6 8 6 8
Mean 0.08 15.66 3.67 5.96 0.06 0.29 0.13 0.22 0.07 1.58 0.19 3.22
SD 0.07 20.30 4.76 9.86 0.06 0.35 0.14 0.28 0.09 2.45 0.09 7.74
Median 0.06 6.12 2.17 2.81 0.05 0.14 0.08 0.13 0.03 0.55 0.15 0.26
High Dose
(n)
8 7 7 7 8 7 7 7 8 7 8 7
Mean 0.01 2.65 2.06 1.73 0.14 0.05 0.09 0.07 0.01 1.30 0.49 1.18
SD 0.02 1.74 1.24 1.05 0.34 0.02 0.12 0.10 0.02 1.48 1.07 2.05
Median 0 1.96 2.02 1.71 0.01 0.05 0.03 0.07 0 0.72 0.11 0.19
doi:10.1371/journal.pone.0055438.t007
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observed transcytosis inhibition that was shown to be mainly
dependent on IgAs [27] and the absence of mucosal IgAs
detection. We are postulating that the current antibody detection
assay may not detect the full IgA antibody repertoire and further
optimization is required. IgGs could also act in synergy with IgAs
for optimal antiviral activities for blocking early steps of HIV
transfer and infection at the mucosal sites [92]. We postulate that a
prophylactic HIV-1 vaccine as MYM-V101 that elicits mucosal
anti-gp41 antibodies in the range of 5–10 ng/mL or more (at least
1010 molecules of antibodies/mL of secretion) could efficiently
block mucosal HIV-1 acquisition from semen of HIV-1 acutely
infected men, which generally contains only 102 to 105 cell-free
infectious particles or thousands of HIV-infected cells [64,93,94].
The mucosal immune system of the male reproductive tract in
human [95,96] and macaque [97] has been studied only recently.
These studies have revealed the presence of antibodies but also of
HIV-1 target cells like dendritic cells, Langerhans cells and T
lymphocytes, explaining why the penile foreskin, inner foreskin
mucosal epithelium, glans and urethra, are potential sites of HIV-1
acquisition in men. These observations are suggesting that
vaccines eliciting mucosal immunity reaching the male reproduc-
tive tract could protect men from acquiring HIV. In subsequent
human trials, the vaccine safety and immunogenicity will also be
tested in men, in parallel to women for monitoring vaccine-
induced antibodies in the genital tract of both genders.
Virus-like particles (VLPs) and enveloped VLPs such as
virosomes harbour antigens at their surface, which are seen as
repetitive motifs that are efficiently recognized by B cell surface
antibodies, leading to their activation. Most VLP-based vaccines
are employing adjuvant such as alum salts and Toll-like receptor
agonists, while influenza-virosomes as enveloped VLPs are used as
stand-alone products. Therefore, comparing the immune respons-
es induced by both adjuvanted VLP and virosome is difficult,
especially if pre-existing immunity impact the vaccine-induce
immune response. Most people have natural pre-existing immu-
nity against influenza, comprizing both humoral and cellular
immunity (CD4+ and CD8+ T cells), which can be beneficial to
vaccination with influenza-virosomes [57]. Influenza-specific
antibodies were shown to bind to virosomes and facilitate their
delivery inside the endosomes of antigen presenting cells,
favouring a Th2 response characterized by a robust antibody
production, as observed in our Phase I study.
Antigen cross-presentation [98] leading to CTL induction is also
possible with virosomes. However, the immunodominant human
CTL epitopes ERYLKDQQL and CSGKLIC in the HXB2 gp41
ectodomain (HIV gp41 CTL epitope data base) are absent from
our P1 peptide used for vaccination, which renders unlikely the
induction of CD8+ T cell response. Meanwhile, it was important to
verify this aspect and in vitro stimulation of PBMC with P1 peptide
followed by intracellular cytokine staining was unable to reveal P1-
specific CD4+ or CD8+ Th1 response, although the threshold
sensitivity of this method might be too weak for detecting low level
of cell-mediated response.
Figure 3. In vitro HIV-1 transcytosis inhibition by vaginal
antibodies. Vaginal samples were collected from placebo and MYM-
V101 vaccinated groups for exploratory work on transcytosis. Panel A
(Visit 9/week 25) and B (Visit 10/week 29) are showing the measured
mean values of transcytosis inhibition with standard deviations
(histogram bars), with the indicated median values for LD and HD
subjects within the bars. Percentages of transcytosis inhibitions were
determined in three independent experiments. Samples were defined
as positive when the transcytosis inhibitions were above 50% and
reproduced in at least 2 experiments. Samples indicated by the (x)
symbol means that they are negative for transcytosis, as they had only 1
measurement above 50% but the mean of the different experiments
has generated a mean value above 50% (see method section). For each
subject, the corresponding DDCT value for P1-specific IgGs and IgAs is
indicated: Samples with values above 1.996 are positive for the
presence of specific antibodies. Low Dose (LD) dark grey bars, High
Dose (HD) light grey bars and placebo with white bars. Panel C is
showing all individual transcytosis data of each placebo and MYM-V101
subject from each representative experiment at week 25 and 29,
allowing an overall qualitative comparison of the presence of
transcytosis inhibition activity in vaginal samples. Placebo week 25
(opened square) compared with MYM-V101 week 25 (black circle), and
placebo week 29 (opened triangle), as compared to MYM-V101 week 29
(black triangle).
doi:10.1371/journal.pone.0055438.g003
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Both IgG or IgA antibodies may bind to their respective Fc
receptor [99] and trigger various viral clearance mechanisms
through Fc-mediated effector functions: Complement activation
[100], antibody-mediated phagocytosis [101,102], or engagement
of antibodies with NK cells, neutrophils or macrophages that leads
to ADCC [103–107]. The potential protective role of ADCC
induced by prophylactic vaccination was already reported in the
vaginal tract of vaccinated NHP with virosome-gp41 [27] and
serum of vaccinated subjects with ALVAC and AIDSVAX that
developed antibodies toward the gp120 [22]. Presence of HIV
specific mucosal antibodies capable of ADCC activity were also
shown to reduce risk of vertical transmission to breastfed infants of
HIV-1 positive women [108]. Therefore, ADCC activity may
represent an important arm of the immune defense against HIV-1.
Due to insufficient material, such binding non-neutralizing
antibodies with ADCC activity could not be tested in this Phase
I study but they will be part of future clinical investigations.
The idea of inducing IgAs as important and complementary
players with IgGs in mucosal and systemic protection represents a
new avenue in the HIV-1 vaccine field. It will be interesting to
determine in the future if blood and mucosal antibodies toward the
same antigen have different or similar epitope specificities,
antibody isotype and how this may impact the antiviral functions
in the systemic and mucosal immune compartments.
This Phase I represents the ‘‘Proof of Principle’’ that it is
possible to elicit both specific IgGs and IgAs in circulation, as well
as in vaginal and intestinal mucosal tissues, using virosome-based
vaccines. The current study did not allow a broad coverage of
potential antiviral activities. With recent in vitro immune assay
developments, a spectrum of innovative immuno-monitoring
investigations will be explored and future clinical trials will benefit
from cutting edge ultrasensitive antibody detection assays com-
bined with new functional antibody assays for evaluating various
antiviral activities. These investigations will provide new insights
regarding protective immune mechanisms from blood and/or
mucosal compartments, as well as new potential surrogate markers
of protection. In this study, the presence of vaccine-induced
mucosal anti-gp41 antibodies with antiviral activities has con-
firmed the previous results in NHP [27], which further supports
the approach of gp41-virosome as a promising vaccine strategy to
induce mucosal antibodies for reducing sexually-transmitted HIV-
1.
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